Sprim Consulting   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Orlando FL United States (2001)

Organization Overview

First Clinical Trial
2005
NCT00599430
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ObvioHealth | Obvio Health | Sprim Advanced Life Sciences | Sprim ALS | SPRIM ALS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdominal Pain (Phase 4)

Clostridium Infections (Phase 3)

Communicable Diseases (Phase 3)

Constipation (Phase 3)

Diarrhea (Phase 4)

Dysentery (Phase 4)

Dyspepsia (Phase 3)

Gastrointestinal Diseases (Phase 3)

Infections (Phase 3)

Inflammation (Phase 4)

Influenza, Human (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Metabolic Syndrome (Phase 3)

Overweight (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Signs and Symptoms, Digestive (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 31